Benign Prostatic Hyperplasia Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 09, 2015 06:52 EST

This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2, 2015 Pipeline Review of “Benign Prostatic Hyperplasia” addition with 47 market data tables and 16 figures, spread across 131 pages is . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Discussed/Mentioned in this Research: Addex Therapeutics Ltd, AmVac AG, AndroScience Corporation, Aphios Corporation, Ausio Pharmaceuticals, LLC, BCWorld Pharm Co. Ltd., Biolab Sanus Farmaceutica Ltda., Chong Kun Dang Pharmaceutical Corp., Dongkook Pharmaceutical Co., Ltd., Euroscreen S.A., Hanmi Pharmaceuticals, Co. Ltd., IntelGenx Corp., Jeil Pharmaceutical Co., Ltd., KAEL-GemVax Co., Ltd., Kaken Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Mezzion Pharma Co. Ltd., Monosol Rx, LLC, Nymox Pharmaceutical Corporation, Ono Pharmaceutical Co., Ltd., Quest PharmaTech Inc., SK Chemicals Co., Ltd., SOM Innovation Biotech SL, Sophiris Bio, Inc. and Yungjin Pharm. Co., Ltd. Drugs Profile Discussed in this Research: (dutasteride + tadalafil), (solifenacin succinate + tamsulosin hydrochloride), (tamsulosin hydrochloride + dutasteride), ADX-68692, AMV-110, ASC-JM.X2, AUS-131, BCWPE-004, BL-214, CKD-902, ESN-364, fexapotide triflutate, HCP-1303, HIP-1402, INT-0031, L-1AD3, MCS-2, Micselon, NCE-403, ONO-8430506, S-40542, SL-052, Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia, SOM-2391, SOM-2393, Sperol, Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology, tadalafil, talaporfin sodium, tamsulosin hydrochloride CR, tamsulosin hydrochloride DR, tertomotide, topsalysin, udenafil, YBH-1603 and YOB-1604 Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license) Scope: • The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Benign Prostatic Hyperplasia and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Benign Prostatic Hyperplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Benign Prostatic Hyperplasia pipeline on the basis of target, MoA, route of administration and molecule type • Latest news and deals relating related to pipeline products Reasons to buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Explore More Research Report on Men's Health Therapeutics Market. In this fast track generation, every human being especially male section of the society is requiring regular scrutiny of their health. As the market of Men’s Health therapeutics is centric to certain users only thereby the demands of the pharmaceuticals will only rise when the complexities will be on a hike. This may not be tagged as a marketing strategy but with stressful lifestyle, unknowingly this has really become the question of the hour. In recent times, erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) are two problems that have become common among this section of the humanity. Together they account to nearly 80% of the men’s health market. But Male hypogonadism with 8.6% is no less to compete for. The annual cost of treatment is also higher in comparison to the general drugs available at the therapeutic segments. In fact the pharmaceuticals companies are trying their level best in terms of discovering new drugs to combat the disease in a quick mode. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries